PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Extension Data Bolster Case Against Amyloid Therapy Coverage Restrictions

donanemablecanemabanti-amyloid monoclonal antibodyamyloid-targeting therapyAlzheimer's diseaseARIAARIA-EAPOEMedicare coverageCMSevidence reviewneuropharmacology Neurology / Neuropharmacology

Background Information

Amyloid therapies show promise in Alzheimer's treatment.

Understanding the long-term safety and efficacy of amyloid-targeting therapies is crucial for Alzheimer's treatment. Extension data show continued benefit with no new safety signals; gradual donanemab titration reduces ARIA risk. The study supports reconsideration of Medicare's coverage policy for amyloid-targeting therapies, but further real-world data may be needed. Amyloid-targeting therapies show sustained benefits and manageable safety profiles.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A, Alzheimer's Disease Neuroimaging Initiative

Citation: Boustani M, Klein EG, Zimmer JA, et al. Further data to address the Alzheimer's coverage with evidence development questions. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(8):e71724. doi:10.1002/alz.71724

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.